These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 25419452)

  • 1. Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes.
    Peene B; Benhalima K
    Ther Adv Endocrinol Metab; 2014 Oct; 5(5):124-36. PubMed ID: 25419452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
    Cuypers J; Mathieu C; Benhalima K
    Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks Associated with SGLT2 Inhibitors: An Overview.
    Singh M; Kumar A
    Curr Drug Saf; 2018; 13(2):84-91. PubMed ID: 29485006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.
    Seufert J
    Diabetes Metab Syndr Obes; 2015; 8():543-54. PubMed ID: 26609242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging treatments in type 2 diabetes: focus on canagliflozin.
    Rosiak M; Grzeszczak S; Kosior DA; PostuĊ‚a M
    Ther Clin Risk Manag; 2014; 10():683-9. PubMed ID: 25187722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes.
    Moses RG; Colagiuri S; Pollock C
    Australas Med J; 2014; 7(10):405-15. PubMed ID: 25379062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
    Saisho Y
    Diseases; 2020 May; 8(2):. PubMed ID: 32403420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The renal effects of SGLT2 inhibitors and a mini-review of the literature.
    Andrianesis V; Glykofridi S; Doupis J
    Ther Adv Endocrinol Metab; 2016 Dec; 7(5-6):212-228. PubMed ID: 28203358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Interventions of Novel SGLT2 Inhibitors Against Metabolic Disorders: Transforming the Association into Perspectives.
    Irshad K; Akash MSH; Rehman K; Sharif H
    Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2169-2180. PubMed ID: 34139987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG
    Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.
    Demin O; Yakovleva T; Kolobkov D; Demin O
    Front Pharmacol; 2014; 5():218. PubMed ID: 25352807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes.
    A Oliveros R; V Pham S; R Bailey S; J Chilton R
    Eur Endocrinol; 2014 Aug; 10(2):117-123. PubMed ID: 29872475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary.
    Mascolo A; Di Napoli R; Balzano N; Cappetta D; Urbanek K; De Angelis A; Scisciola L; Di Meo I; Sullo MG; Rafaniello C; Sportiello L
    Front Cardiovasc Med; 2022; 9():1010693. PubMed ID: 36211584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives.
    John M; Gopinath D; Jagesh R
    Indian J Endocrinol Metab; 2016; 20(1):22-31. PubMed ID: 26904465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes.
    Mikhail N
    World J Diabetes; 2014 Dec; 5(6):854-9. PubMed ID: 25512787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.